BioCentury
ARTICLE | Product Development

ImmunoGen’s milestone year

How 2019 could yield first evidence ImmunoGen’s new growth strategy is working

January 18, 2019 9:43 PM UTC

Nearly three years after refocusing the company to boost long-term value creation, ImmunoGen Inc. expects 2019 to be the year the changes will begin to bear fruit, starting with Phase III data from its lead candidate mirvetuximab soravtansine.

ImmunoGen was one of the first antibody-drug conjugate (ADC) companies when it was founded in 1981, and has since built up its coffers via discovery and development deals with pharma companies (see “TAP’s Big Finish”). ...

BCIQ Company Profiles

ImmunoGen Inc.